Daily Hand-Held Vibration Therapy for the Reduction of Chemotherapy Induced Peripheral Neuropathy

Inclusion Criteria

• Able to provide informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization
• Have completed chemotherapy >= 60 days prior to enrollment
• Were exposed to neurotoxic chemotherapy with one or more of the following agents in the following doses: * Paclitaxel (cumulative dose: >= 300 mg/m^2) * Docetaxel (cumulative dose: >= 100 mg/m^2) * Nab-paclitaxel (cumulative dose: >= 750 mg/m^2) * Oxaliplatin (cumulative dose: >= 510 mg/m^2) * Carboplatin (cumulative dose: >= 600 mg/m^2) * Cisplatin (cumulative dose: >= 200 mg/m^2) * Vincristine (cumulative dose: >= 4 mg/m^2) * Bortezomib (cumulative dose: >= 16 mg/m)
• Continue to display evidence of sensory CIPN in the hands rated at a grade >= 2 according the National Cancer Institute’s Common Toxicity Criteria-Adverse Events (NCI-CTC-AE, version 5.0) scale >= 60 days post chemotherapy
• If solid tumor cancer, can have must have non-metastatic cancer as long as there is either no evidence of disease (NED), or stable disease (SD) via imaging, and is >= 60 days post-chemotherapy
• Agree to return to clinic for required study related measurements at specified intervals

Exclusion Criteria

• Have pre-existing neuropathy affecting the hands not related to chemotherapy (e.g., carpal tunnel syndrome, nerve compression, etc.)
• Known diagnosis of diabetes mellitus
• Known contraindications for vibration therapy to hands, including deep venous thrombosis of the upper extremity or ongoing skin infection
• Will be receiving concurrent radiation of the upper-extremity